Clinical Response to Induction Chemotherapy Predicts Outcome after Combined-Modality Therapy in Inflammatory Breast Cancer. (2nd January 2019)

• Record Type: Journal Article
• Authors: Loi, Mauro; Dunant, Ariane; Ghith, Sahar; Cascales-Garcia, Almudena Maria; Mazouni, Chafika; Pistilli, Barbara; Mathieu, Marie-Christine; Deutsch, Eric; Arriagada, Rodrigo; Rivera, Sofia
• Is Part Of: Cancer investigation. Volume 37:Number 1(2019)
• Page Start: 29
• Page End: 38
• Publication Date: 2019-01-02
• Subjects: Breast cancer -- chemotherapy -- outcome research -- radiation oncology; Cancer -- Periodicals; Oncology -- Periodicals; Medical Oncology -- Periodicals; Neoplasms -- Periodicals; 616.994
• DOI: 10.1080/07357907.2018.1564325
• Languages: English
• ISSNs: 0735-7907

Abstract

Abstract: Purpose: To assess predictors of outcome in a cohort of Inflammatory Breast Cancer (IBC) patients receiving induction chemotherapy followed by local treatment. Methods: We retrospectively reviewed 95 non-metastatic IBC patient files. Results: Complete clinical response (cCR) was obtained in 15 (16%) patients. Median follow up was 13.4 years (IC95%: 10.4–14.6). Loco-regional control (LC), disease-free survival (DFS), and overall survival (OS) at 5 years were 85%, 41%, and 55%, respectively; cCR was associated with better DFS and OS in multivariate analyses adjusted for age ( p = 0.02). Conclusions: Clinical response to upfront chemotherapy predicts the outcome of patients affected by IBC.